New hope for rare epilepsy: fenfluramine made available for dravet patients
NCT ID NCT04437004
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study offers fenfluramine to people with Dravet syndrome whose seizures have not improved with other medications. The goal is to provide access to the drug and monitor its safety. Participants must have a genetic diagnosis of Dravet syndrome and have tried all available seizure medicines without success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, Los Angeles
Los Angeles, California, 90095-1752, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Virtual therapy helps kids with rare epilepsy gain daily living skills
- New hope for dravet syndrome: phase 3 trial of EPX-100 aims to cut seizures
- Could a repurposed drug tame seizures in adult dravet patients?
- New hope for kids with rare seizure disorder: ION337 trial launches
- Could a seizure drug also prevent sudden death in dravet syndrome?